Dual mRNA Nanoparticles Reverse Chondrocyte Aging to Treat Osteoarthritis
Lipid nanoparticles co-delivering SOX5 and SOX9 mRNA synergistically reversed chondrocyte senescence and restored cartilage in rat OA models.
Summary
Researchers engineered optimized lipid nanoparticles (LNPs) to simultaneously deliver two transcription factor mRNAs — SOX5 and SOX9 — into aging chondrocytes. SOX9 drives synthesis of key cartilage matrix proteins (collagen II, aggrecan), while SOX5 amplifies SOX9 activity and independently reverses cellular senescence. Seven LNP formulations were screened; the best-performing composition was validated in vitro and in a surgically induced rat osteoarthritis model. The dual-mRNA approach outperformed single-gene treatments by reducing inflammatory markers, suppressing senescence hallmarks (p16, p21, SA-β-Gal), and significantly restoring cartilage structure and joint function, offering a promising disease-modifying therapy for OA.
Detailed Summary
Osteoarthritis (OA) affects over 300 million people globally and lacks disease-modifying treatments. A central driver of OA is chondrocyte senescence: aging cartilage cells accumulate and secrete inflammatory cytokines and matrix-degrading enzymes (SASP), eroding the extracellular matrix and propagating joint degeneration. Existing therapies — NSAIDs, corticosteroids, hyaluronic acid — provide only symptomatic relief. This study aimed to address OA at its cellular root by delivering regenerative transcription factors directly into chondrocytes via mRNA nanotechnology.
The researchers designed seven lipid nanoparticle (LNP) formulations varying the molar ratios of SM-102 (ionizable lipid, 40–60%), cholesterol, DSPC, and DMG-PEG2000. Using luciferase mRNA as a reporter, they screened all seven formulations for transfection efficiency in primary rat chondrocytes in vitro, then narrowed to the top three for intra-articular injection in healthy rats, monitored by IVIS bioluminescence imaging at 12 and 24 hours. The lead formulation was then loaded with SOX5 and SOX9 mRNAs and tested in hydrogen peroxide–induced senescent chondrocyte cultures and in an anterior cruciate ligament transection (ACLT) rat OA model.
Key results showed that co-delivery of SOX5 and SOX9 mRNA produced synergistic effects exceeding either factor alone. In senescent chondrocytes, the combination markedly reduced SA-β-Gal activity and expression of senescence markers p16-INK4A and p21-CDKN1A, while strongly upregulating type II collagen and aggrecan production. Inflammatory cytokines (IL-1β, IL-6, TNF-α) and matrix-degrading enzymes (MMP-13, ADAMTS-5) were significantly suppressed. Importantly, LNP cytotoxicity was negligible across tested concentrations in both chondrocytes and bone marrow mesenchymal stem cells. In the rat ACLT model, intra-articular injection of SOX5/SOX9@LNPs substantially improved cartilage regeneration histologically, reduced synovial inflammation, and restored joint function compared to single-factor or vehicle controls.
Mechanistically, SOX9 re-establishes core chondrogenic gene programs, while SOX5 (lacking its own transactivation domain) amplifies SOX9 transcriptional output at cartilage-specific enhancers and independently reactivates pro-regenerative genes such as HMGB2, reversing senescence-associated epigenetic silencing without altering cell identity — a key safety advantage over Yamanaka factor reprogramming approaches.
This work establishes a clinically attractive platform: mRNA is transient (no genomic integration risk), LNPs are already clinically validated (COVID-19 vaccines), and intra-articular delivery is a routine clinical procedure. The synergistic dual-mRNA strategy represents a meaningful advance toward disease-modifying OA therapy, though translation will require further optimization for human joint anatomy, longer-term safety data, and demonstration of durability beyond the rat model timeframe.
Key Findings
- Seven LNP formulations were screened; optimal SM-102-based LNPs achieved highest chondrocyte transfection in vitro and in vivo.
- SOX5+SOX9 mRNA co-delivery synergistically reduced senescence markers p16, p21, and SA-β-Gal in senescent chondrocytes.
- Dual-mRNA LNPs upregulated collagen II and aggrecan while suppressing MMP-13, ADAMTS-5, and inflammatory cytokines.
- In ACLT rat OA model, SOX5/SOX9@LNPs significantly improved cartilage regeneration and joint function vs single-gene controls.
- LNP formulations showed negligible cytotoxicity across therapeutic concentrations in chondrocytes and mesenchymal stem cells.
Methodology
Seven SM-102-based LNP formulations were screened using luciferase mRNA reporters in primary rat chondrocytes (in vitro luminescence) and intra-articular injection in rats (IVIS imaging). The lead formulation co-encapsulating SOX5 and SOX9 mRNA was evaluated in H2O2-induced senescent chondrocytes and a surgically induced ACLT rat OA model, with histological, immunofluorescence, ELISA, and functional readouts.
Study Limitations
Findings are limited to a rat ACLT model, which may not fully replicate human OA biomechanics or disease chronicity. Long-term durability of mRNA expression and therapeutic effect beyond the study window was not assessed. Human chondrocyte penetration through denser adult cartilage matrix and immune responses in immunocompetent human joints remain to be characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: